Furthermore, factors associated with survival including age (<50, ≥50 and <40, ≥40), median tumour size (25 mm), lymph node status, pathological stage, early stage breast cancer (ESBC) and locally advanced breast cancer (LABC), tumour grade, lymphovascular invasion, oestrogen receptor and progesterone receptor status, HER2/neu status, and molecular subtype of the patients were analysed (Table 2). This evidence concerns the gene ERBB2 and breast carcinoma.